Abstract: Compounds of formula I ##STR1## wherein R represents hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.5 -C.sub.7 cycloalkyl, methylene-dioxy or phenyl, which may be substituted by one or two groups independently selected from hydroxy, halogen, nitro, C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 alkoxy; R.sub.1 and R.sub.2 independently represent hydrogen, COOR.sub.3, --CONR.sub.4 R.sub.5, ##STR2## --OCONR.sub.4 R.sub.5, --OCOR.sub.3, --NR.sub.4 R.sub.5, --OCOOR.sub.6, --NR.sub.3 COR.sub.7, --NR.sub.CONR.sub.4 R.sub.5, --N.dbd.CH--NR.sub.4 R.sub.5, NO.sub.2, CN, OH, SR.sub.3, wherein R.sub.3 is hydrogen or C.sub.1 -C.sub.6 alkyl, R.sub.4 and R.sub.5 independently are hydrogen or C.sub.1 -C.sub.6 alkyl, R.sub.6 is C.sub.1 -C.sub.6 alkyl, and R.sub.7 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 alkoxy, with the proviso that R.sub.1 and R.sub.2 cannot be hydrogen at the same time; X is oxygen or sulphur; Y represents a C.sub.2 -C.sub.6 alkylene chain or a C.sub.5 -C.sub.

Abstract: Isoindole compounds of the formula (I) ##STR1## wherein R.sub.1 represents hydrogen; C.sub.1 -C.sub.6 alkyl; benzyl optionally substituted with halogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, methylenedioxy; C.sub.2 -C.sub.8 aliphatic acyl; benzoyl optionally substituted with halogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, C.sub.2 -C.sub.6 alkanoyl, C.sub.2 -C.sub.6 alkanoyloxy, C.sub.1 -C.sub.4 alkyl, trifluoromethyl, methylenedioxy;R.sub.2 -R.sub.3 are selected independently from hydrogen; halogen; C.sub.1 -C.sub.4 alkyl; trifluoromethyl; hydroxy; nitro; amino; mono or di C.sub.1 -C.sub.4 alkylamino; cyano; C.sub.1 -C.sub.6 alkoxy; C.sub.2 -C.sub.6 alkoxycarbonyl;Y is ethylene, or a straight or branched alkylene chain containing from 3 to 6 carbon atoms, and the salts thereof of pharmaceutically acceptable acids. The compounds possess antianginal activity and are used in the preparation of medicaments for antianginal therapy.

Abstract: Salts of glycosaminoglycans (heparin, its fractions or fragments which are supersulfated, dermatan sulfate, heparan sulfate, and modified heparins) with bases of formula (I), ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 represent H, alkyl, or cycloalkyl; R.sub.5 and R.sub.6 represent H, or alkyl; R.sub.7 and R.sub.8 represent H or alkyl; n and m are integers from 1-4 and X is --O--CO--O--, which salts have the pharmacological properties of the glycosaminoglycans themselves, and are orally and rectally administrable.

Abstract: Benzoxazinone and benzothiazinone derivatives of formula ##STR1## wherein R represents hydrogen, (C.sub.2-6)alkyl, (C.sub.5-7)cycloalkyl, phenyl, substituted phenyl; R.sub.1 and R.sub.2 independently represents hydrogen, halogen, (C.sub.1-4)alkyl, (C.sub.1-4)alkoxy or trifluoromethyl; X is oxygen or sulfur; Y is (C.sub.2-6)alkylene or (C.sub.5-7)cycloalkylene; and salts therewith of pharmaceutically acceptable acids. The compounds possess cardiovascular activity with high specificity for the coronary district.

Abstract: An orientation and loading device for vials, and in particular syringe vials (A), which are disposed with their axis substantially vertical. The vials are fed by a feeder (1) to an endless conveyor (5) comprising a plurality of orientable cells (6), each of which removably receives a fed vial. In an assigned position (R) of the conveyor (5) the cells (6) and hence the vials received therein lie substantially horizontal above a container (7) provided with several cavities (8) for receiving the vials and intended to form part of the package in which the vials are sold. When in this horizontal position, a release means (9) operates to release the vials (A) from the cells (6) and cause them to fall into the underlying container (7), for example a thermoformed container.

Abstract: Compounds of the general formula I ##STR1## wherein R.sub.1 is hydrogen or methyl;R.sub.2 and R.sub.3, which are the same or different, represent hydrogen or methyl, or taken together, form the amidine system to which an imidazole or imidazoline ring is bound;R.sub.4 is a linear or branched C.sub.1 -C.sub.10 alkyl group; cycloalkyl, aryl, aralkyl or hetaryl group;R.sub.5 is hydrogen or methyl;A is a propylene chain optionally substituted by one or two methyl groups in one or more of the positions thereof; a chain of formula --HN--CH.sub.2 --CH.sub.2 -- or of formula --N.dbd.CH--CH.sub.2 --; a 1,4-cyclohexylene group optionally substituted by one or more methyl groups; a 1,4- phenylene group optionally substituted by one or more halogen atoms, alkyl groups or C.sub.1 -C.sub.4 alkoxy group with the proviso that, when R.sub.4 is methyl or ethyl and R.sub.1 =R.sub.2 =R.sub.3 =R.sub.

Abstract: Pharmaceutical compositions are described which have antithrombotic activity suitable for the prevention and for the therapy of cardiac infarcts, cerebral infarcts and venous thrombosis. They contain as the active component a fraction of heparin which has been modified by nitrogen desulfatation and succinylation, which fraction contains less than 10% of the N-sulfate groups of the heparin starting material and more than 0.6 succinyl radicals per disaccharide unit. The method of treatment is described.

Abstract: A process for the removal of components having low or no anticoagulant activity from a glucosaminoglucan is described which comprises subjecting said glucosaminoglucan in the form of a salt in an aqueous solution to flow across a membrane suitable for ultrafiltration, hyperfiltration (inverse osmosis) or dialysis with partial passage through said membrane, whereby fractions of low activity go through the membrane and fractions of higher activity do not go through the membrane and are concentrated. The membrane suitable for ultrafiltration may have a nominal molecular cut-off between 1000 and 15,000. The membrane suitable for dialysis may have a nominal molecular cut-off at less than 30,000. The glucosaminoglucan may be heparin in the form of the sodium or calcuium salt.

Abstract: The invention relates to succinylated proteins, with a degree of succinylation of between 20 to 100%, containing from 0.1 to 20% by weight of iron, obtained by treating succinylated proteins with iron salts in suitable pH ranges. The compounds in question, which are completely tolerated, are characterized by an optimum bioavailability of iron.

Abstract: A process for the preparation of the calcium salt of heparin containing an amount of sodium by weight not in excess of 0.1% and containing an amount of calcium by weight not less than 9.5% is described, which comprises subjecting a solution of sodium heparinate to dialysis, hyperfiltration (inverse osmosis) or ultrafiltration by means of a semi-permeable membrane and isolating the calcium heparinate with anticoagulant activity essentially equal to the anticoagulant activity of the sodium heparinate. For the ultrafiltration, a membrane may be used in the form of a planar sheet or a membrane in the form of a spiral or "needle" having a molecular nominal cut-off at 20,000 Dalton. For the hyperfiltration (inverse osmosis), a membrane may be used having a rejection of sodium ion between 0 and 75%. For the dialysis, a membrane may be used in the form of multiple sheets or a coiled tube or hollow fibers. A plurality of dialyzers in series or in parallel is used.

Abstract: Pharmaceutical compositions for use in the relief of acute pulmonary edema, different types of shock including anaphylactic shock, shock induced by bacterial endotoxins, and hyperfibrinolysis induced by substances which activate plasminogen, consist of solutions of an ester of L-arginine with an aliphatic alcohol in water at a pH between 5.5 and 8.5. The compositions may be provided in unit dosage form containing 0.25-100 mg of active substance per kilogram of body weight of the subject in need of treatment and are administered through the parenteral route. The esters may be provided in the form of a salt with a pharmaceutically acceptable organic or inorganic acid. The esters may be with methyl or ethyl alcohol. The compositions are more effective than aspirin and aprotinin.

Abstract: Enzyme immobilization is carried out be adding to a suspension of polysaccharide in aqueous medium, a vinyl monomer and an enzyme, then a catalyst comprising a metallic salt, and irradiating the resulting mixture with ultraviolet light to cause polymerization and form a copolymer of the polysaccharide having enzymatic activity. The metallic salt is preferably a ferric salt and the vinyl monomer is preferably methylacrylate, glycidylmethacrylate, acrylonitride, bis-acyloylpiperazine or symmetrical N, N', N"-trisacryloyl-hexahydrotriazine.

Abstract: Pharmaceutical compositions exhibiting antiphlogistic, antipyretic, analgesic activity and high gastroenteric tolerance are described. The active ingredient is imidazole salicylate of chemical formula (I).

Abstract: Pharmaceutical compositions for use in the relief of acute pulmonary edema, different types of shock including anaphylactic shock, shock induced by bacterial endotoxins, and hyperfibrinolysis induced by substances which activate plasminogen, consist of solutions of an ester of L-arginine with an aliphatic alcohol in water at a pH between 5.5 and 8.5. The compositions may be provided in unit dosage form containing 0.25-100 mg of active substance and are administered through the parenteral route. The esters may be provided in the form of a salt with a pharmaceutically acceptable organic or inorganic acid. The esters may be with methyl or ethyl alcohol. The compositions are more effective than aspirin and aprotinin.

Abstract: A novel reactor for enzymatic reactions comprises a flow cell which is constituted by two semi-blocks having a planar surface. The enzyme is immobilized on one of the semi-blocks while a thin channel is provided on the face of the other semi-block. The two semi-blocks are hermetically closed. The substrate solution follows a tangential motion and travels with a laminar flow. The reactor permits to achieve 90% contact with the enzyme and may be used continuously.

Abstract: Pharmaceutical compositions containing a corticosteroid and an ester of L-arginine with an aliphatic alcohol exhibit a synergistic effect in the protection against shock. The corticosteroid may be 6-.alpha.-methylprednisolone-21-hemisuccinate sodium salt and the L-arginine ester may be the methyl ester in the form of the hydrochloride salt.